logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (6)
  • CSV
  • BibTeX
  • EndNote
  • All Results (6)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A,  et al.
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A,  et al.
2024-09-01 • IJTLD OPEN
2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

Rekart M, Thit P, Oluya M, Moe S, Hasan T,  et al.
2024-07-01 • IJTLD OPEN
2024-07-01 • IJTLD OPEN

Background

Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...

Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance

Cox HS, Kebede YYK, Allamuratova S, Ismailov G, Davletmuratova Z,  et al.
2006-10-01 • PLOS Medicine
2006-10-01 • PLOS Medicine
BACKGROUND: The DOTS (directly observed treatment short-course) strategy for tuberculosis (TB) control is recommended by the World Health Organization globally. However, there are few st...

Risk factors associated with default from multi- and extensively drug-resistant tuberculosis treatment, Uzbekistan: a retrospective cohort analysis

Lalor MK, Greig J, Allamuratova S, Althomsons S, Tigay Z,  et al.
2013-11-06 • PLOS One
2013-11-06 • PLOS One
BACKGROUND
The Médecins Sans Frontières project of Uzbekistan has provided multidrug-resistant tuberculosis treatment in the Karakalpakstan region since 2003. Rates of default from t...

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan

Nair P, Hasan T, Zaw KK, Allamuratova S, Ismailov A,  et al.
2022-07-01 • International Journal of Tuberculosis and Lung Disease
2022-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is ...